InspireMD

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InspireMD reports strong Q1 performance, eyes future growth opportunities

InspireMD's Q1 2024 showcased revenue growth and promising trial results, but challenges in gross profit and rising expenses. Strategic agreements and upcoming product approvals present opportunities for future growth and innovation.

InspireMD reports revenue growth, faces cost challenges, eyes U.S. launch

InspireMD's Q2 2024 performance reflects revenue growth but challenges in managing costs and achieving profitability.
The company's strengths lie in groundbreaking clinical outcomes, successful financings, and preparations for a U.S. commercial launch.
While facing cost and financial challenges, InspireMD has opportunities to drive market expansion, innovation, and capitalize on its strong cash position.
Balancing growth initiatives with cost control will be key for InspireMD's sustainable financial success and market competitiveness.

InspireMD reports 16% revenue growth in Q3 2024 earnings call

InspireMD's Q3 performance reflects revenue growth but challenges in profitability due to cost dynamics.
The company's strategic strengths lie in international sales, product innovation, and U.S. market focus.
Opportunities include FDA approvals, market expansion, and strong financial position for growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

InspireMD, Inc. (NASDAQ:NSPR ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.

InspireMD, Inc. (NSPR) Q4 2022 Earnings Call Transcript

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 -

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

-Conference call and webcast to be held at 8:30 a.m. EDT-

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being held November 15 – 19 in New York City.

InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium

InspireMD, Inc. (NASDAQ:NSPR ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

InspireMD, Inc. (NSPR) Q3 2022 Earnings Call Transcript

- Generated 38.8% growth in CGuard™ revenue year-over-year -

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

-Conference call and webcast to be held at 8:30 a.m. EDT- -Conference call and webcast to be held at 8:30 a.m. EDT-

InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update

TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held September 16-19, 2022, at the Boston Convention and Exhibition Center in Boston, MA.

InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

TOLEDO, Ohio & TEL AVIV, Israel--(BUSINESS WIRE)-- #CRO--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization. InspireMD, which was founded

NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

InspireMD, Inc. (NASDAQ:NSPR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2022 Results - Earnings Call Transcript

- Generated 47.8% growth in CGuard™ revenue year-over-year -

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Conference call and webcast to be held at 8:30 a.m. EDT -

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

Credited with performing the first ever endovascular repair procedure in 1990 Credited with performing the first ever endovascular repair procedure in 1990

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

Successful live case transmission again demonstrated CGuard's™ differentiated patient protection features and ease of use Successful live case transmission again demonstrated CGuard's™ differentiated patient protection features and ease of use

InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

Coupa Software

HealthEquity

OceanPal

Science Applications International

Some of the stocks that may grab investor focus today are: Wall Street expects Science Applications International Corporation (NYSE: SAIC) to report quarterly earnings at $1.77 per share on revenue of $1.93 billion before the opening bell. SAIC shares rose 2.2% to $90.00 in after-hours trading.

5 Stocks To Watch For June 6, 2022

Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS) Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS)

InspireMD's CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

InspireMD, Inc. (NASDAQ:NSPR ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to InspireMD First Quarter 2022 Earnings Call. [Operator Instructions] At this time, I'd like to turn the call over to your host, Chuck Padala, LifeSci Advisors.

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2022 Results - Earnings Call Transcript

- 20% growth in CGuard™ revenue Year-over-Year -

InspireMD Reports First Quarter 2022 Financial Results and Business Update

Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET

InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

Tuesday, March 22nd @ 2 p.m. ET Tuesday, March 22nd @ 2 p.m. ET

InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q4 2021 Results - Earnings Call Transcript

- CGuard™ Revenue Generated 87.5% growth over Q4'20 and 55.9% Year-over-Year –-

InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET-

News for InspireMD Stock (NSPR)